[144] Avidity Biosciences, Inc. SEC Filing

Rhea-AI Filing Summary

Avidity Biosciences (RNA) filed a Form 144 reporting a proposed sale of 50,000 common shares to be executed through Morgan Stanley Smith Barney on 09/05/2025, with an aggregate market value of $2,423,500 based on the filing. The shares were acquired on 09/05/2025 by exercise of stock options and paid in cash. The filer also reported prior 10b5-1 sales of 25,000 shares on 08/28/2025 generating gross proceeds of $1,234,700. The filing includes the required representation that the seller is not aware of undisclosed material adverse information and references reliance on Rule 10b5-1 trading instructions where applicable.

Insights

Securities Analyst

TL;DR Routine insider sale following option exercise; modestly dilutive but likely non-material for investors.

The filing documents an insider or related person exercising options and proposing to sell 50,000 common shares valued at $2.42 million, executed through a broker on NASDAQ. The presence of prior 10b5-1 sales of 25,000 shares indicates a staged disposition plan rather than a single large block sale. This is standard compliance activity; the transaction increases free float but, given the issuer's reported outstanding shares of 128,653,337, the size is small relative to total equity and unlikely to materially affect market capitalization by itself.

Corporate Governance Expert

TL;DR Disclosure appears complete for a Form 144; timing and 10b5-1 reference reduce governance concerns.

The filer disclosed acquisition details, nature of acquisition (option exercise), payment method, broker details and prior 10b5-1 sales, and included the statutory representation regarding material non-public information. These elements satisfy typical Rule 144 notice expectations and suggest adherence to insider trading protocols. No red flags such as unexplained transfers, gifts, or unusual counterparty arrangements are present in the disclosed fields.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	50000	2423500.00	128653337	09/05/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/05/2025	Exercise of Stock Options	Issuer			50000	09/05/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for SARAH BOYCE 10578 Science Center Drive, Suite 125 San Diego CA 92121	Common	08/28/2025	25000	1234700.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did Avidity Biosciences (RNA) report on Form 144?

The filer reported a proposed sale of 50,000 common shares via Morgan Stanley Smith Barney on 09/05/2025, valued at $2,423,500.

How were the 50,000 shares acquired according to the filing?

The filing states the shares were acquired on 09/05/2025 through the exercise of stock options and paid for in cash.

Were there any recent sales by the same person before this notice?

Yes; the filer reported 10b5-1 sales of 25,000 shares on 08/28/2025 with gross proceeds of $1,234,700.

Through which broker will the proposed sale be executed?

The proposed sale is to be executed through Morgan Stanley Smith Barney LLC on the NASDAQ.

Does the Form 144 include a statement about material non-public information?

Yes; the signer represents they do not know any material adverse information about the issuer that is not publicly disclosed and references Rule 10b5-1 where applicable.